Evidence map›Paper›PMID 33389319›Full record

ArticleAIDS and behavior2021

A Scoping Review of HIV Pre-exposure Prophylaxis Stigma and Implications for Stigma-Reduction Interventions for Men and Transwomen Who Have Sex with Men.

A Lina Rosengren, Corina Lelutiu-Weinberger, E Wilbur Woodhouse, Priyadharshiny Sandanapitchai, Lisa B Hightow-Weidman

Erratum issued Registry-linked trialOpen access · greenAbstract readScoping Review
In one paragraph

Article in AIDS and behavior, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT07560046 (Combating Related Epidemics in HCV Through Simplified Testing and Treatment. A Cluster Randomized Trial of Point-of-care Hepatitis C Testing and Treatment Among Key Populations), which is not on this map. Cited by 41 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 2 pooled it
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07560046 phase4not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Combating Related Epidemics in HCV Through Simplified Testing and Treatment. A Cluster Randomized Trial of Point-of-care Hepatitis C Testing and Treatment Among Key Populations

TypeinterventionalSponsorDuke UniversityRan2026 to 2030Enrolled1,280ConditionsHIV - Human Immunodeficiency Virus, Hepatitis B Virus (HBV), HEPATITIS C (HCV)ArmsCepheid GeneXpert HCV Test, Abbott Determine HIV - 1/2 Ag/Ab, Abbott Determine HbsAg 2, Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]
3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Discrimination and misconceptions about human immunodeficiency virus among gay and bisexual men.Health psychology : official journal of the Division of Health Psychology, American Psychological Association · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Exploring Willingness to Use Long-Acting Injectable PrEP Among Sexual and Gender Minoritized People Accessing Pharmacies.AIDS education and prevention : official publication of the International Society for AIDS Education · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

A Lina RosengrenDivision of Infectious Diseases, Department of Medicine, University of North Carolina, 130 Mason Farm Road, Chapel Hill, NC, 27599, USA. lina_roho@med.unc.edu.ORCID http://orcid.org/0000-0002-4256-706X
Corina Lelutiu-WeinbergerRutgers Biomedical and Health Sciences, School of Nursing, François-Xavier Bagnoud Center, Rutgers University, 65 Bergen Street, Room 846N, Newark, NJ, 07107, USA.
E Wilbur WoodhouseDepartment of Medicine, Vanderbilt University Medical center, 1161 21st Avenue South, Nashville, TN, 37122, USA.
Priyadharshiny SandanapitchaiFrançois-Xavier Bagnoud Center, Rutgers University, 65 Bergen Street, Newark, NJ, 07107, USA.
Lisa B Hightow-WeidmanDivision of Infectious Diseases, Department of Medicine, University of North Carolina, 130 Mason Farm Road, Chapel Hill, NC, 27599, USA.
Rutgers, The State University of New Jersey · USUniversity of North Carolina at Chapel Hill · USVanderbilt University Medical Center · US

Funding

The UNC/Emory Center for Innovative Technology (iTech) across the prevention and care continuumU19HD089881 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HIGHTOW-WEIDMAN, LISA B, SULLIVAN, PATRICK SEAN · 2016 to 2022
$35.8M
Increasing engagement and improving HIV care outcomes via stigma reduction in an online social networking intervention among racially diverse young men who have sex with men and transgender womenR01MD013623 · NIMHD · UNIVERSITY OF PENNSYLVANIA · PI BAUERMEISTER, JOSE ARTURO, MUESSIG, KATHRYN E · 2018 to 2022
$3.9M
Health Mpowerment.org: a novel Internet and mobile phone HIV intervention for youR01MH093275 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HIGHTOW-WEIDMAN, LISA B · 2011 to 2015
$2.3M
Addressing stigma among Black MSM in a mobile phone and internet HIV interventionR21MH105292 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BAUERMEISTER, JOSE ARTURO, MUESSIG, KATHRYN E · 2015 to 2016
$443k
NICHD NIH HHS U19 HD089881NIMHD NIH HHS R01 MD013623NIMH NIH HHS R01 MH093275NIMH NIH HHS R21 MH105292
6 · The paper itself

Abstract

HIV remains a public health concern in the United States. Although pre-exposure prophylaxis (PrEP) can be expected to reduce HIV incidence, its uptake, adherence, and persistence remain limited, particularly among highest priority groups such as men who have sex with men and transwomen (MSMTW). Using a socioecological framework, we conducted a scoping review to examine PrEP-related stigma to inform future research, policy, and programmatic planning. Using the PRISMA extension for scoping reviews, we conducted database searches from August 2018 to April 2020 for articles addressing PrEP stigma. Studies were independently screened and coded by three authors, resulting in thematic categorization of several types of PrEP stigma on four socioecological levels. Of 557 references, a final sample of 23 studies was coded, 61% qualitative, and 87% focusing exclusively on MSMTW. Most instances of PrEP-related stigma occurred on the interpersonal level and included associations of PrEP with risk promotion, HIV-related stigma, and promiscuity. Other frequent themes across socioecological levels included provider distrust and discrimination, government and pharmaceutical industry distrust, internalized homonegativity, PrEP efficacy distrust, and anticipated homonegativity. Notably, PrEP was also framed positively as having physical and psychological benefits, and assuming responsibility for protecting one's community via PrEP awareness-raising. PrEP-related stigma persists, demanding interventions to modify its impact. Leveraging PrEP-positive discourses to challenge PrEP stigma is an emerging avenue, alongside efforts to increase provider willingness to promote PrEP routinely by reducing provider bias, aligning with the national strategy to End the HIV Epidemic.

Indexed as

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisSexual and Gender MinoritiesHomosexuality, MaleHumansMaleUnited StatesAnti-HIV AgentsHIVMSMPrEPStigmaTranswomen

Identifiers

PMID33389319
PMCPMC10539076
OpenAlexW3119355253

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.